Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Filippo Pietrantonio

Showing results (101-110 of 323) with videos related to

Pageof 33
Sort By:
Clinical Colorectal Cancer|April 27, 2019
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma PeritoneiAlessandra Raimondi, Salvatore Corallo, Monica Niger, et al.
Clinical Colorectal Cancer|July 2, 2020
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target PopulationMarta Schirripa, Floriana Nappo, Chiara Cremolini, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Targeted Oncology|November 6, 2015
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal CancerFilippo Pietrantonio, Filippo de Braud, Massimo Milione, et al.
Cancers|April 13, 2023
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical TrialsDavide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, et al.
Critical Reviews in Oncology/Hematology|November 24, 2024
Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paperUmberto Malapelle, Valentina Angerilli, Rossana Intini, et al.
JAMA Network Open|January 8, 2024
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-AnalysisFederico Nichetti, Simone Rota, Paolo Ambrosini, et al.
Nature Communications|June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapiesMariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Clinical Colorectal Cancer|April 7, 2019
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentRoberto Moretto, Federica Morano, Elena Ongaro, et al.
Pageof 33

Showing results (101-110 of 323) with videos related to

Sort By:
Pageof 33
Clinical Colorectal Cancer|April 27, 2019
Metronomic Capecitabine With Cyclophosphamide Regimen in Unresectable or Relapsed Pseudomyxoma PeritoneiAlessandra Raimondi, Salvatore Corallo, Monica Niger, et al.
Clinical Colorectal Cancer|July 2, 2020
KRAS G12C Metastatic Colorectal Cancer: Specific Features of a New Emerging Target PopulationMarta Schirripa, Floriana Nappo, Chiara Cremolini, et al.
International Journal of Molecular Sciences|April 24, 2015
Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenaseFelicia Stefania Falvella, Marta Caporale, Stefania Cheli, et al.
British Journal of Clinical Pharmacology|March 19, 2015
DPD and UGT1A1 deficiency in colorectal cancer patients receiving triplet chemotherapy with fluoropyrimidines, oxaliplatin and irinotecanFelicia Stefania Falvella, Stefania Cheli, Antonia Martinetti, et al.
Targeted Oncology|November 6, 2015
Dose-Dense Temozolomide in Patients with MGMT-Silenced Chemorefractory Colorectal CancerFilippo Pietrantonio, Filippo de Braud, Massimo Milione, et al.
Cancers|April 13, 2023
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical TrialsDavide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, et al.
Critical Reviews in Oncology/Hematology|November 24, 2024
Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paperUmberto Malapelle, Valentina Angerilli, Rossana Intini, et al.
JAMA Network Open|January 8, 2024
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer: A Systematic Review and Meta-AnalysisFederico Nichetti, Simone Rota, Paolo Ambrosini, et al.
Nature Communications|June 14, 2018
Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapiesMariangela Russo, Simona Lamba, Annalisa Lorenzato, et al.
Clinical Colorectal Cancer|April 7, 2019
Lack of Benefit From Anti-EGFR Treatment in RAS and BRAF Wild-type Metastatic Colorectal Cancer With Mucinous Histology or Mucinous ComponentRoberto Moretto, Federica Morano, Elena Ongaro, et al.
Pageof 33